PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brings together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world class organisations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Specifically, this initiative funded by the Innovative Medicines Initiative (IMI), focuses on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe. Since the development of preventative measures such as a vaccine and monoclonal antibodies are well under way, PROMISE aims to prepare for the introduction of such treatments and prophylactic interventions.

Download the PROMISE factsheet here.

The initiative builds on RESCEU (Respiratory Syncytial Virus Consortium in Europe), another IMI project which generated valuable insights into the impact of RSV on healthcare systems and society, amongst other significant results, such as creating a biorepository to assist future research.

PROMISE was launched in November 2021 and will end in April 2024.
It is led by the University of Edinburgh (UEDIN), the University Medical Centre Utrecht (UMCU) and the pharmaceutical company Sanofi.

PROMISE Facts & Figures

Start date:
1 november 2021

End date:
30 april 2024

Call:
IMI2 – CALL 22

Type of action:
Research and innovation action (RIA)

Grant agreement number:
101034339

Project coordinator:
The University of Edinburgh and University Medical Centre Utrecht

Project leader:
Sanofi

CONTRIBUTIONS

Total cost:

7.024.387 €

IMI Funding:

3.744.375 €

EFPIA in kind:

3.280.012 €